I’m a Dietitian Taking A GLP-1. These Are My Go-To Simple Meals

These medications changed not only my appetite, but the entire way I think about food, hunger, and self-care.
Jelly Roll’s Wife Says He’s Falling ‘In Love With Himself’ After Weight Loss

Jelly Roll’s wife, Bunnie Xo, can see how his recent 200-pound weight loss has transformed his spirit. “He just shaved his face for the first time in 20 years,” Bunnie, 45, told Extra in an interview published on Wednesday, January 7. “I think the coolest part of my husband shaving his face was getting to […]
Study reveals how fast weight returns after ending GLP-1 drugs

Post Content
Novo Nordisk Gets Discounted as Investors Look Past the Next Phase of GLP-1 Growth
George Mason trial: New pill aims to sustain weight loss after GLP-1s

GLP-1 medications like Ozempic and Wegovy have transformed obesity treatment, but maintaining weight loss after the medications stop remains a challenge.
Joel Habener, Whose Research Led to Weight-Loss Drugs, Dies at 88

His discovery of the protein fragment GLP-1 was crucial in the development of Ozempic, Wegovy and other blockbuster obesity and diabetes treatments.
You’re Doing This Right — And Still Not Burning Fat | Dr. Mandell

Many people eat healthy, cut sugar, and still struggle with stubborn fat, low energy, or blood sugar swings. In this video, Dr. Mandell explains why fat loss is not just about what you eat, but how your body interprets a meal at the physiological level. Learn how eating speed influences digestion, insulin signaling, cortisol, and […]
Novo Nordisk’s (NVO)

Novo Nordisk’s (NVO) Novo Nordisk A/S Sponsored ADR Class B BATS:NVO KalaGhazi Based on a detailed technical analysis of Novo Nordisk’s (NVO) stock in the context of its recent groundbreaking commercial and regulatory developments, including the U.S. launch of the oral Wegovy pill and its availability on Amazon Pharmacy, several key Fibonacci retracement levels have […]
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve

Johnson & Johnson JNJ recently signed a landmark agreement with the Trump administration to lower drug prices in the United States. Following this deal, JNJ joins several other large-cap pharma companies that signed similar deals with the government in 2025. These companies include Amgen, Bristol Myers, privately-held Boehringer Ingelheim, Genentech (a member of the Roche Group), Gilead Sciences, GSK […]
Amylyx selects AMX-0318 as development candidate

Amylyx Pharmaceuticals Inc. has nominated AMX-0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases.